Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.

Hdl Handle:
http://hdl.handle.net/10147/621275
Title:
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
Authors:
Thirion, P; Piedbois, P; Buyse, M; O'Dwyer, P J; Cunningham, D; Man, A; Greco, F A; Colucci, G; Köhne, C H; Di Constanzo, F; Piga, A; Palmeri, S; Dufour, P; Cassano, A; Pajkos, G; Pensel, R A; Aykan, N F; Marsh, J; Seymour, M T
Citation:
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. 2001, 84 (5):611-20 Br. J. Cancer
Journal:
British journal of cancer
Issue Date:
2-Mar-2001
URI:
http://hdl.handle.net/10147/621275
DOI:
10.1054/bjoc.2000.1669
PubMed ID:
11237380
Abstract:
Two meta-analyses were conducted to quantify the benefit of combining alpha-IFN to 5FU in advanced colorectal cancer in terms of tumour response and survival. Analyses were based on a total of 3254 individual patient data provided by principal investigators of each trial. The meta-analysis of 5FU +/- LV vs. 5FU +/- LV + alpha-IFN combined 12 trials and 1766 patients. The meta-analysis failed to show any statistically significant difference between the two treatment groups in terms of tumour response or survival. Overall tumour response rates were 25% for patients receiving no alpha-IFN vs. 24% for patients receiving alpha-IFN (relative risk, RR = 1.02), and median survivals were 11.4 months for patients receiving no alpha-IFN vs. 11.5 months for patients receiving alpha-IFN (hazard ratio, HR = 0.95). The meta-analysis of 5FU + LV vs. 5FU + alpha-IFN combined 7 trials, and 1488 patients. This meta-analysis showed an advantage for 5FU + LV over 5FU + alpha-IFN which was statistically significant in terms of tumour response (23% vs. 18%; RR = 1.26;P = 0.042), and of a borderline significance for overall survival (HR = 1.11;P = 0.066). Metastases confined to the liver and primary rectal tumours were independent favourable prognostic factors for tumour response, whereas good performance status, metastases confined to the liver or confined to the lung, and primary tumour in the rectum were independent favourable prognostic factors for survival. We conclude that alpha-IFN does not increase the efficacy of 5FU or of 5FU + LV, and that 5FU + alpha-IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer.
Item Type:
Article
Language:
en
Keywords:
ALPHA-INTERFERON; INTERFERON; CANCER, COLORECTAL; 5-FLUOROURACIL
MeSH:
Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Interferon-alpha; Leucovorin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis
ISSN:
0007-0920

Full metadata record

DC FieldValue Language
dc.contributor.authorThirion, Pen
dc.contributor.authorPiedbois, Pen
dc.contributor.authorBuyse, Men
dc.contributor.authorO'Dwyer, P Jen
dc.contributor.authorCunningham, Den
dc.contributor.authorMan, Aen
dc.contributor.authorGreco, F Aen
dc.contributor.authorColucci, Gen
dc.contributor.authorKöhne, C Hen
dc.contributor.authorDi Constanzo, Fen
dc.contributor.authorPiga, Aen
dc.contributor.authorPalmeri, Sen
dc.contributor.authorDufour, Pen
dc.contributor.authorCassano, Aen
dc.contributor.authorPajkos, Gen
dc.contributor.authorPensel, R Aen
dc.contributor.authorAykan, N Fen
dc.contributor.authorMarsh, Jen
dc.contributor.authorSeymour, M Ten
dc.date.accessioned2017-04-20T08:33:08Z-
dc.date.available2017-04-20T08:33:08Z-
dc.date.issued2001-03-02-
dc.identifier.citationAlpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. 2001, 84 (5):611-20 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid11237380-
dc.identifier.doi10.1054/bjoc.2000.1669-
dc.identifier.urihttp://hdl.handle.net/10147/621275-
dc.description.abstractTwo meta-analyses were conducted to quantify the benefit of combining alpha-IFN to 5FU in advanced colorectal cancer in terms of tumour response and survival. Analyses were based on a total of 3254 individual patient data provided by principal investigators of each trial. The meta-analysis of 5FU +/- LV vs. 5FU +/- LV + alpha-IFN combined 12 trials and 1766 patients. The meta-analysis failed to show any statistically significant difference between the two treatment groups in terms of tumour response or survival. Overall tumour response rates were 25% for patients receiving no alpha-IFN vs. 24% for patients receiving alpha-IFN (relative risk, RR = 1.02), and median survivals were 11.4 months for patients receiving no alpha-IFN vs. 11.5 months for patients receiving alpha-IFN (hazard ratio, HR = 0.95). The meta-analysis of 5FU + LV vs. 5FU + alpha-IFN combined 7 trials, and 1488 patients. This meta-analysis showed an advantage for 5FU + LV over 5FU + alpha-IFN which was statistically significant in terms of tumour response (23% vs. 18%; RR = 1.26;P = 0.042), and of a borderline significance for overall survival (HR = 1.11;P = 0.066). Metastases confined to the liver and primary rectal tumours were independent favourable prognostic factors for tumour response, whereas good performance status, metastases confined to the liver or confined to the lung, and primary tumour in the rectum were independent favourable prognostic factors for survival. We conclude that alpha-IFN does not increase the efficacy of 5FU or of 5FU + LV, and that 5FU + alpha-IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer.en
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.subjectALPHA-INTERFERONen
dc.subjectINTERFERONen
dc.subjectCANCER, COLORECTALen
dc.subject5-FLUOROURACILen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshInterferon-alpha-
dc.subject.meshLeucovorin-
dc.subject.meshPrognosis-
dc.subject.meshProportional Hazards Models-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshSurvival Analysis-
dc.titleAlpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.en
dc.typeArticleen
dc.identifier.journalBritish journal of canceren
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.